New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
about
Concepts and clinical use of ultra-long basal insulinInsulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectivesrDNA insulin glargine U300 - a critical appraisalPharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.The past, present, and future of basal insulins.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.A primer on concentrated insulins: what an internist should know.Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.Weight Management in Patients with Type 1 Diabetes and Obesity.Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress".Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.Understanding concentrated insulins: a systematic review of randomized controlled trials.Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).Clinical Challenges With Concentrated Insulins: Setting the Record Straight.Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements.[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.Advances in Basal Insulin Therapy.Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
P2860
Q26770354-FB8639E0-DE7C-46B4-A3BC-97DDA5EEC63CQ28074690-57318890-EE0D-4BD6-8253-FE71FF67CC2AQ28077366-09717676-5921-4038-8C97-76F5677B98F4Q30244827-A9D2B8B9-10E5-4E10-B733-131C473329F8Q30248803-9FCF727C-5B61-49CE-A216-C296E3B8B570Q33884391-B49B8FA7-8895-47B6-B307-7CD5EC20FD55Q35772552-1A609628-5F00-4ACE-B046-9B9FF79B04C9Q36554243-225C4F0A-7CB8-4649-A74F-1B7E34814221Q37054680-496E829E-3DD3-423E-819E-9A343C9D695EQ37343841-E799FF90-8F8D-4139-B12D-CA0047868755Q37343847-D77FF552-46D0-48EF-AA9B-36307C5613E5Q37737461-01B04AEE-0A18-49A8-9AE1-4BA2D94B2DB3Q38386958-D73CF369-F339-4D82-AEE8-77DAAB5F06DEQ38597991-70EB444E-EE2B-4DE3-A9BE-1143C8C715BEQ38618376-7EAC2663-D6A6-4E1B-A028-2C864C0E5398Q38692387-FEB86AF9-8A11-4CF7-B569-4E9549086D71Q38715053-8965C007-ADC8-4E1A-B71A-F5632A3F85CDQ38754210-EBD864A9-EC03-4668-8142-6D924620BF68Q38971612-4B035BF4-686E-4BB9-888D-5694454F10C2Q39791634-2454369D-E443-4B43-855B-76F05A228EB7Q41504692-39EACA66-AD6E-42FF-9BAB-76E0ACFF1165Q43158349-C267177B-5F9C-4028-9E36-57729F6E42A2Q44372707-C94CC3A3-F486-45F4-A80F-0148EDCEA7DBQ46199321-3D4378FB-EE31-43B3-AF33-91E737A6B45FQ47192711-C8BBE373-50DC-42D1-BFA4-8871FF5D646AQ47322851-FF5AA1C0-FD37-4980-9C76-125B11C93B1AQ48201978-09AD42B4-66B1-461D-AAAF-06351BCB6263Q49899781-B5D7285E-22FC-4586-9BD3-D787BA482381Q50351384-6650FE21-146A-476C-BBBF-98333613E363Q52605864-770E4838-8804-42EE-AD51-150D856191C0Q52606010-8BC466A4-9932-4E18-9381-6415889CC78BQ52836101-B6C5AE32-7BAC-4ECD-AE8C-77015569441CQ53448284-5753665A-F694-4257-95F6-277F8E8F5F81Q53449720-16B5F714-B539-44E6-880E-57FD67526DF7Q55046951-2F0E0073-AA0E-43B0-A4D5-0C12CB8CAAB1Q55309585-57E608A5-452F-4FC4-AB35-EB4AD5176309Q55374453-E8316EFC-8D5C-483B-BA39-8606F585A087Q58763121-7BE084DA-5832-403D-B4FA-4E2BF2703AE6
P2860
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@en
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@nl
type
label
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@en
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@nl
prefLabel
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@en
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@nl
P2093
P356
P1433
P1476
New Insulin Glargine 300 Units ...... el Clinical Trial (EDITION 4).
@en
P2093
Geremia B Bolli
Maria Rojeski
Matthew C Riddle
Melanie Espinasse
Monika Ziemen
Philip D Home
Richard M Bergenstal
P304
P356
10.2337/DC15-0249
P407
P577
2015-06-17T00:00:00Z